Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Pathol Int. 2011 Aug;61(8):456-60. doi: 10.1111/j.1440-1827.2011.02694.x.
There is limited data regarding the association between the expression of cell cycle-regulating molecules and the response of patients with urothelial carcinoma in situ (CIS) to bacillus Calmette-Guerin (BCG) therapy. To examine the relationship between p16, pRb and p53 expression in bladder CIS and patient response to initial BCG therapy, we performed immunohistochemical studies for 27 patients with bladder CIS. Overexpression of p16, pRb, and p53 was observed in 37%, 41%, and 48% of patients, respectively. Initial BCG therapy was effective in 21 patients (78%). Coexistence of papillary urothelial carcinoma, depth (pTa or pT1) and grade of coexisting papillary carcinoma did not affect the response to BCG therapy. pRb overexpression had a significant relationship to poor response to BCG therapy (P= 0.027). The results of this study indicate that overexpression of pRb in bladder CIS predicts poor response of intravesical BCG instillation and status of p16 and p53 may not be predictive of initial BCG failure.
关于细胞周期调节分子的表达与膀胱癌原位癌（CIS）患者对卡介苗（BCG）治疗反应之间的关系，数据有限。为了研究膀胱 CIS 中 p16、pRb 和 p53 表达与患者对初始 BCG 治疗反应之间的关系，我们对 27 例膀胱 CIS 患者进行了免疫组织化学研究。分别有 37%、41%和 48%的患者出现 p16、pRb 和 p53 的过度表达。21 例患者（78%）初始 BCG 治疗有效。存在乳头状尿路上皮癌、深度（pTa 或 pT1）和共存乳头状癌的分级并不影响 BCG 治疗的反应。pRb 过度表达与 BCG 治疗反应不良有显著关系（P=0.027）。本研究结果表明，膀胱 CIS 中 pRb 的过度表达预示着膀胱内 BCG 灌注的反应不良，而 p16 和 p53 的状态可能不能预测初始 BCG 失败。
